title: Upper-extremity deep venous thrombosis after whole blood donation: report of three cases from a single blood center.
abstract: BACKGROUND
  There are two upper-extremity deep venous thrombosis (UEDVT) cases after whole blood donation reported in the English medical literature. Three additional UEDVT cases after whole blood donation were reported to our blood center within a 13-month period.
  
  
  METHODS
  A case study was done for each case in collaboration with a clinical physician. A description of the donation event, donor demographics, risk factors for thrombosis, treatment, and outcome were described.
  
  
  RESULTS
  A 33-year-old woman and two 17-year-old, first-time-donating men presented with arm pain, swelling, and bruising within hours to 3 days after donation. Two had distal UEDVTs in the basilic or brachial veins, and one had a proximal UEDVT in the subclavian and axillary veins extending into the basilic vein. One donor (woman) had known risk factors for DVT and the other two did not. Anticoagulant therapy was initiated on all patients and was continued for 3, 4, and 9 months. Two donors with the distal UEDVTs recovered completely while the donor with the proximal UEDVT was treated with anticoagulation for 9 months and continued to have a slight residual, nonobstructive thrombosis. The donor was switched to low-dose aspirin prevention. The two donors reported in the literature had complete resolution of thrombosis.
  
  
  CONCLUSIONS
  Four of five donors recovered completely after anticoagulation treatment for UEDVT, including two of three donors in this study. A review of all cases in the medical literature, including 20 recent Australian cases described in an abstract, provides a more complete description of this adverse donation injury.
authors.affiliation: Medical Office, American Red Cross Blood Services, SE Michigan Region, Detroit, Michigan.
authors.forename: Bruce
authors.initials: B
authors.lastname: Newman
authors.affiliation: Division of Hematology/Oncology, Carman Ann Adams Children's Hospital of Michigan, Wayne State University, Detroit, Michigan.
authors.forename: Madhvi
authors.initials: M
authors.lastname: Rajpurkar
authors.affiliation: Division of Hematology/Oncology, Carman Ann Adams Children's Hospital of Michigan, Wayne State University, Detroit, Michigan.
authors.forename: Bulent
authors.initials: B
authors.lastname: Ozgonenel
authors.affiliation: Hematology Section, Port Huron Hospital, Port Huron, Michigan.
authors.forename: Anup
authors.initials: A
authors.lastname: Lal
authors.affiliation: Hematology Section, Henry Ford Hospital, Detroit, Michigan.
authors.forename: Philip
authors.initials: P
authors.lastname: Kuriakose
mesh_terms: D000293:Adolescent; D000328:Adult; D000736:Androstenes / Q000009:adverse effects; D001782:Blood Donors; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects; D057915:Drug Substitution; D004630:Emergencies; D017984:Enoxaparin / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D018962:Phlebotomy / Q000009:adverse effects*; D011401:Promoter Regions, Genetic / Q000235:genetics; D011516:Prothrombin / Q000235:genetics; D019851:Thrombophilia / Q000235:genetics; D056824:Upper Extremity Deep Vein Thrombosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000736:Androstenes; D003278:Contraceptives, Oral, Hormonal; D017984:Enoxaparin; C534342:drospirenone and ethinyl estradiol combination; D004997:Ethinyl Estradiol; D014859:Warfarin; D011516:Prothrombin